Suppr超能文献

富马酸替诺福韦二吡呋酯挽救治疗拉米夫定和阿德福韦酯治疗失败的慢性乙型肝炎。

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.

机构信息

Liver Transplant Unit, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia.

出版信息

Gut. 2011 Feb;60(2):247-54. doi: 10.1136/gut.2010.223206. Epub 2010 Oct 29.

Abstract

OBJECTIVE

To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV).

DESIGN

A prospective open-label study of TDF 300 mg daily. Patients receiving combination ADV/LAM prior to baseline were switched to TDF/LAM.

SETTING

Multiple tertiary referral centres.

METHODS

Sixty patients were enrolled. The median age was 48.5 years (range 21e80), 46 (77%) were male and 40 (67%) were HBeAg positive. Thirty-eight patients (63%) were switched from ADV to TDF, the remainder from ADV/LAM to TDF/LAM. At baseline, substitutions conferring resistance to LAM or ADV were present in 20 patients (33%) and 17 patients (28%), respectively. The median baseline viral load was 5.33 log₁₀ IU/ml (range 2.81-8.04). Patients initially treated with TDF monotherapy with persistent viral replication at or after 24 weeks were switched to TDF/LAM. The main outcome measures were change in HBV viral load from baseline and percentage of patients achieving an undetectable viral load (<15 IU/ml).

RESULTS

Results are reported at 96 weeks of treatment. One patient discontinued TDF at 10 days due to rash. The time-weighted change in viral load from baseline to week 12 was -2.19 log10 IU/ml overall. The median change in HBV DNA from baseline to weeks 12, 24, 48 and 96 was -2.86, -3.23, -3.75 and -4.03 log₁₀ IU/ml, respectively. At 48 and 96 weeks, 27/59 (46%) and 38/59 (64%) patients achieved a HBV DNA <15 IU/ml. The response was independent of baseline LAM therapy or mutations conferring ADV resistance.

CONCLUSIONS

In heavily pretreated patients with a high rate of genotypic resistance, TDF retains significant activity against HBV although this appears diminished in comparison with studies of naïve patients.

摘要

目的

评估替诺福韦酯(TDF)在先前拉米夫定(LAM)治疗失败且存在显著病毒复制(HBeAg 阳性者 HBV DNA >10⁵ 拷贝/ml,HBeAg 阴性者 HBV DNA >10⁴ 拷贝/ml)的慢性乙型肝炎病毒(HBV)感染成人患者中的疗效,这些患者在接受阿德福韦酯(ADV)至少 24 周治疗后仍有病毒复制。

设计

一项替诺福韦酯 300mg 每日治疗的前瞻性开放标签研究。基线时接受 ADV/LAM 联合治疗的患者转换为 TDF/LAM。

地点

多个三级转诊中心。

方法

共纳入 60 例患者。中位年龄为 48.5 岁(范围 21-80),46 例(77%)为男性,40 例(67%)为 HBeAg 阳性。38 例(63%)患者从 ADV 转换为 TDF,其余患者从 ADV/LAM 转换为 TDF/LAM。基线时,20 例(33%)和 17 例(28%)患者存在对 LAM 或 ADV 耐药的替代突变。中位基线病毒载量为 5.33log₁₀IU/ml(范围 2.81-8.04)。初始接受 TDF 单药治疗且治疗 24 周后仍有病毒复制的患者转换为 TDF/LAM。主要观察指标为从基线开始的 HBV 病毒载量变化和达到病毒载量不可检测(<15IU/ml)的患者比例。

结果

治疗 96 周时报告结果。1 例患者因皮疹在 10 天内停用 TDF。从基线到第 12 周时病毒载量的时间加权变化总体为-2.19log10IU/ml。从基线到第 12、24、48 和 96 周时 HBV DNA 的中位变化分别为-2.86、-3.23、-3.75 和-4.03log₁₀IU/ml。在第 48 和 96 周时,分别有 27/59(46%)和 38/59(64%)患者的 HBV DNA <15IU/ml。该反应与基线 LAM 治疗或 ADV 耐药相关突变无关。

结论

在大量预先治疗且基因型耐药率较高的患者中,TDF 对 HBV 仍具有显著活性,但与初治患者的研究相比,这种活性似乎减弱。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验